Suven Life Sciences Ltd
22 February 2025 13:45|BSE : 530239|NSE : SUVEN|ISIN : INE495B01038
22 February 2025 13:45|BSE : 530239
NSE : SUVEN|ISIN : INE495B01038
Suven Life Sciences is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. The goal is to be the leading biopharmaceutical company focused on the treatment of dementia, a condition characterized by a significant decline in mental capacity and impaired daily function. The Company is targeting Central Nervous System (CNS) indications where there is a high unmet medical need, growing patient populations and with possible commercialization options. Suven has a wholly owned subsidiary, Suven Neurosciences, Inc., USA, focused on clinical development activities of Suven molecules from phase 2, Proof-of-Concept (POC) studies
Suven Life Sciences is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. The goal is to be the leading biopharmaceutical company focused on the treatment of dementia, a condition characterized by a significant decline in mental capacity and impaired daily function. The Company is targeting Central Nervous System (CNS) indications where there is a high unmet medical need, growing patient populations and with possible commercialization options. Suven has a wholly owned subsidiary, Suven Neurosciences, Inc., USA, focused on clinical development activities of Suven molecules from phase 2, Proof-of-Concept (POC) studies
FAQs
How to buy Suven Life Sciences Ltd shares?
What is the current Market Cap of Suven Life Sciences Ltd?
What is the current PE and PB ratio of Suven Life Sciences Ltd?
Open Free Demat Account
Kickstart your investment journey
